Lori Anne Kunkel net worth and biography

Lori Kunkel Biography and Net Worth

Director of Enliven Therapeutics

Lori currently serves on the Board of Directors of Nurix Therapeutics, ORIC Pharmaceuticals, and K36 Therapeutics. Previously, she was the acting Chief Medical Officer at Loxo Oncology (acquired by Eli Lilly and Company) and subsequently served on their board.

She has previously served on the board of directors of Curis Inc., Maverick Therapeutics, Harpoon Therapeutics and Tocagen.

She also served as the Chief Medical Officer at Pharmacyclics (acquired by AbbVie) and Proteolix (acquired by Onyx Pharmaceuticals), where she contributed to the global approvals of Imbruvica (ibrutinib) and Kyprolis (carfilzomib), respectively.

What is Lori Anne Kunkel's net worth?: The estimated net worth of Lori Anne Kunkel is at least $1.87 million as of June 5th, 2026. Ms. Kunkel owns 51,884 shares of Enliven Therapeutics stock worth more than $1,873,531 as of June 10th. This net worth estimate does not reflect any other assets that Ms. Kunkel may own. Learn More about Lori Anne Kunkel's net worth.
How do I contact Lori Anne Kunkel?: The corporate mailing address for Ms. Kunkel and other Enliven Therapeutics executives is 309 Beacon Street Suite 300 Office 341, Brookline MA, 02446. Enliven Therapeutics can also be reached via phone at 617-927-9989 and via email at [email protected]. Learn More on Lori Anne Kunkel's contact information.
Has Lori Anne Kunkel been buying or selling shares of Enliven Therapeutics?: Within the last three months, Lori Anne Kunkel has sold $345,400.00 in shares of Enliven Therapeutics stock. Most recently, Lori Anne Kunkel sold 10,000 shares of the business's stock in a transaction on Friday, June 5th. The shares were sold at an average price of $34.54, for a transaction totalling $345,400.00. Following the completion of the sale, the director now directly owns 51,884 shares of the company's stock, valued at $1,792,073.36. Learn More on Lori Anne Kunkel's trading history.
Who are Enliven Therapeutics' active insiders?: Enliven Therapeutics' insider roster includes Rahul Ballal (Director), Rishi Gupta (Director), Richard Heyman (Chairman of the Board of Directors), Benjamin Hohl (Chief Financial Officer and Head of Corporate Development), Samuel Kintz (Co-founder, Chief Executive Officer, and Member of the Board of Directors), Lori Kunkel (Director), Joseph Lyssikatos (Co-founder, Chief Scientific Officer), and Anish Patel (Co-founder and Chief Operating Officer). Learn More on Enliven Therapeutics' active insiders.
Are insiders buying or selling shares of Enliven Therapeutics?: In the last twelve months, insiders at the sold shares 42 times. They sold a total of 449,661 shares worth more than $10,875,846.32. The most recent insider tranaction occured on June, 5th when Director Lori Anne Kunkel sold 10,000 shares worth more than $345,400.00. Insiders at Enliven Therapeutics own 3.0% of the company. Learn More about insider trades at Enliven Therapeutics.
Information on this page was last updated on 6/5/2026.

Lori Anne Kunkel Insider Trading History at Enliven Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/5/2026	Sell	10,000	$34.54	$345,400.00	51,884

Lori Anne Kunkel Buying and Selling Activity at Enliven Therapeutics

Enliven Therapeutics Company Overview

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

Today's Range

Now: $36.84

$35.71

$37.41

50 Day Range

MA: $41.27

$33.63

$48.11

2 Week Range

Now: $36.84

$14.78

$48.53

Volume

64,956 shs

Average Volume

1,110,946 shs

Market Capitalization

$2.24 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.29